𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus

✍ Scribed by David H. Ilson; David Kelsen; Manish Shah; Gary Schwartz; Douglas A. Levine; Jeff Boyd; Marinela Capanu; Benjamin Miron; David Klimstra

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
124 KB
Volume
117
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 trial of talactoferrin in previo
Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma
✍ Eric Jonasch; Walter M. Stadler; Ronald M. Bukowski; Teresa G. Hayes; Atul Varad 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 2 views

## Abstract ## BACKGROUND. Talactoferrin (TLF), a recombinant form of human lactoferrin (hLF), is an immunomodulatory iron‐binding glycoprotein first identified in breast milk. Its immunomodulatory functions include activation of natural killer (NK) and lymphokine‐activated killer cells and enhanc

Prognostic role of cyclooxygenase-2 in n
Prognostic role of cyclooxygenase-2 in neoadjuvant-treated patients with squamous cell carcinoma of the esophagus
✍ Anna Sivula; Christianne J. Buskens; Bastiaan P. van Rees; Caj Haglund; G. Johan 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 93 KB 👁 1 views

## Abstract Based on our previous demonstration that elevated cyclooxygenase‐2 (COX‐2) expression is a prognostic factor for reduced survival in patients with adenocarcinoma of the esophagus, the aim of our study was to analyze the role of COX‐2 expression in esophageal squamous cell carcinoma. We

A Phase II trial of topotecan and gemcit
A Phase II trial of topotecan and gemcitabine in patients with previously treated, advanced nonsmall cell lung carcinoma
✍ David A. Rinaldi; Nancy A. Lormand; Joseph E. Brierre; James L. Cole; Brian C. B 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB 👁 2 views

## Abstract ## BACKGROUND Multiple trials have been performed to evaluate second‐line clinical chemotherapy in patients with advanced nonsmall cell lung carcinoma (NSCLC). However, no single agent or combination has demonstrated superior activity. ## METHODS Patients with advanced NSCLC who had

A phase 2 clinical trial of nab-paclitax
A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma
✍ Evan M. Hersh; Steven J. O'Day; Antoni Ribas; Wolfram E. Samlowski; Michael S. G 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 234 KB 👁 2 views

## Abstract ## BACKGROUND: __nab__‐Paclitaxel (ABI‐007, Abraxane), a 130‐nM, albumin‐bound (__nab__) particle form of Cremophor‐free paclitaxel, is approved for metastatic breast cancer. In the current study, the efficacy and safety of __nab__‐paclitaxel were evaluated in previously treated and ch